Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC22975	GB111-NH2 Featured	GB111-NH2 (Z-Phe-Lys-AOMK) is a novel cysteine cathepsin inhibitor that blocks the activity of cathepsins B, L and S. GB111-NH2 (Z-Phe-Lys-AOMK) inhibits autophagy and increases oxidative stress, specifically trigger macrophage cell death.
DC22648	VMY-1-103	A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
DC20927	CRS-3123	A novel diaryldiamine that inhibits bacterial methionyl-tRNA synthetases in Gram-positive bacteria as a novel agent to treat Clostridium difficile infection (CDI).
DC24099	CC-115 hydrochloride	A novel dual inhibitor of mTOR and DNA-PK with IC50 of 21 nM and 13 nM, respectively.
DC21412	SR-16157	A novel dual-acting steroid sulfatase inhibitor (IC50=0.1 uM) and selective ERα modulator (SERM).
DC22487	Benzenepentacarboxylic Acid Featured	Benzenepentacarboxylic acid is a fluorescent dye that detects and scavenge HO radicals.
DC22768	MP07-66 Featured	A novel FTY720 analog that acts as PP2A activator, disrupts the SET/PP2A interaction devoid of immunosuppressive effects leads to the reactivation of PP2A.
DC23458	AZD 9164	A novel highly potent, selective, long acting muscarinic receptor M3 antagonist with pIC50 of 9.8, 10-fold selectivity over M2 (pIC50=9.0).
DC22883	MK-7288	A novel histamine H3 receptor inverse agonist for the treatment of sleep apnoea syndrome.
DC24012	BI-224436	A novel HIV-1 non-catalytic-site integrase inhibitor (NCINI).
DC22944	NS-3623 Featured	A novel human RBC Cl-conductance blocker (IC50=210 nM) and HERG channel activitor (EC50=79.4 uM, HERG1 channel activation).
DC23936	IQ-R	A novel hypoxia-sensitive fluorescent probe.
DC22386	I-2906	A novel isocitrate lyase (ICL) inhibitor that displays showed excellent anti-Mycobacterium tuberculosisl activities and low cytotoxicity.
DC25013	ARM-1 Featured	A novel LTA4 hydrolase (LTA4H) inhibitor that inhibits LTB4 synthesis in human neutrophils with IC50 of 0.5 uM.
DC22856	ARN-5187	A novel lysosomotropic REV-ERB ligand that has a dual inhibitory activity toward REV-ERB-mediated transcriptional regulation and autophagy.
DC21378	Piromelatine	A novel melatonin melatonin receptor MT1/MT2 and serotonin 5-HT1A/5-HT1D receptor agonist.
DC11928	MPT0B002	A novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
DC11935	PBOX-15	A novel microtubule targeting agent that induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple cancer cells.
DC22773	DSR-71167	A novel mineralocorticoid receptor antagonist (IC50=0.26 uM) with carbonic anhydrase inhibitory activity (IC50=19 uM).
DC11929	ME-344	A novel mitochondrial and mTOR inhibitor with potent anti-cancer activity, inhibits leukemia cell lines with IC50 of 70-260 nM.
DC11775	DS44170716	A novel MPT (mitochondrial permeability transition) inhibitor of that inhibits Ca2+-induced MPT in rat liver isolated mitochondria.
DC22955	LUF7244	A novel negative allosteric modulator of dofetilide binding to the Kv11.1 (hERG) channel with the strongest effect at 10 uM (IC50=3.9 uM).
DC10802	AMPA/kainate antagonist-2	A novel Non-competitive AMPA/kainate antagonist.
DC20293	14-3-3 inhibitor BV2	A novel nonpeptidic inhibitor of 14-3-3 protein-protein interaction that promotes the apoptotic death of cells expressing either wt Bcr-Abl construct or T315I mutation.
DC11930	EDD3	A novel Notch inhibitor that reduces protein expression of NOTCH1, NICD and HES1 in HEK293 cells and downregulates Notch target genes.
DC11910	IPL-576092	A novel orally active, anti-inflammatory compound that inhibits leukocyte infiltration and changes in lung function in response to allergen challenge.
DC23994	Peretinoin	A novel orally available, synthetic retinoid with potential antineoplastic and chemopreventive activities.
DC11811	SCY-078	A novel orally bioavailable fungal beta-1,3-D glucan synthetase inhibitor against Candida species C. glabrata (MIC 0.03 to 0.25 ug/ml), C. parapsilosis (MIC 0.06 to 0.25 ug/ml).
DC22434	POL5551	A novel peptidic, potent and highly selective CXCR4 antagonist with IC50 of 1.7 nM.
DC3161	Prasugrel Featured	A novel platelet inhibitor

Novel inhibitors

Customized Consultation X

Your information is safe with us. * Required Fields.